These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 30608386)

  • 1. Simplified MIPI-B prognostic stratification method can predict the outcome well-retrospective analysis of clinical characteristics and management of newly-diagnosed mantle cell lymphoma patients from China.
    He JS; Chen X; Wei GQ; Sun J; Zheng WY; Shi JM; Wu WJ; Zhao Y; Zheng GF; Huang H; Cai Z
    Medicine (Baltimore); 2019 Jan; 98(1):e13741. PubMed ID: 30608386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.
    Hoster E; Rosenwald A; Berger F; Bernd HW; Hartmann S; Loddenkemper C; Barth TF; Brousse N; Pileri S; Rymkiewicz G; Kodet R; Stilgenbauer S; Forstpointner R; Thieblemont C; Hallek M; Coiffier B; Vehling-Kaiser U; Bouabdallah R; Kanz L; Pfreundschuh M; Schmidt C; Ribrag V; Hiddemann W; Unterhalt M; Kluin-Nelemans JC; Hermine O; Dreyling MH; Klapper W
    J Clin Oncol; 2016 Apr; 34(12):1386-94. PubMed ID: 26926679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database.
    Salek D; Vesela P; Boudova L; Janikova A; Klener P; Vokurka S; Jankovska M; Pytlik R; Belada D; Pirnos J; Moulis M; Kodet R; Michal M; Janousova E; Muzik J; Mayer J; Trněný M
    Leuk Lymphoma; 2014 Apr; 55(4):802-10. PubMed ID: 23772666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network.
    Hoster E; Klapper W; Hermine O; Kluin-Nelemans HC; Walewski J; van Hoof A; Trneny M; Geisler CH; Di Raimondo F; Szymczyk M; Stilgenbauer S; Thieblemont C; Hallek M; Forstpointner R; Pott C; Ribrag V; Doorduijn J; Hiddemann W; Dreyling MH; Unterhalt M
    J Clin Oncol; 2014 May; 32(13):1338-46. PubMed ID: 24687837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of Clinical Characteristics and Prognostic Factors of Patients with Limited-Stage Mantle Cell Lymphoma].
    Sun J; He S; Rong C; Cen H; Tan XH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1123-1128. PubMed ID: 35981371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study.
    Nordström L; Sernbo S; Eden P; Grønbaek K; Kolstad A; Räty R; Karjalainen ML; Geisler C; Ralfkiaer E; Sundström C; Laurell A; Delabie J; Ehinger M; Jerkeman M; Ek S
    Br J Haematol; 2014 Jul; 166(1):98-108. PubMed ID: 24684350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy and Prognosis of Chemotherapy Regimen Containing BTK Inhibitor in Treatment of Recurrent/Refractory Mantle Cell Lymphoma].
    Chen H; Liu XY; Chang Y; Chen ZQ; Li WQ; Zhang L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):125-131. PubMed ID: 38387910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.
    Greenwell IB; Staton AD; Lee MJ; Switchenko JM; Saxe DF; Maly JJ; Blum KA; Grover NS; Mathews SP; Gordon MJ; Danilov AV; Epperla N; Fenske TS; Hamadani M; Park SI; Flowers CR; Cohen JB
    Cancer; 2018 Jun; 124(11):2306-2315. PubMed ID: 29579328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical analysis of the character and prognostic factors of 23 cases of mantle cell lymphoma].
    Liang R; Wang Z; Zhu MN; Hao CX; Zhang N; Wang JH; Zhang T; Yang L; Gu HT; Dong BX; Bai QX; Gao GX; Chen XQ
    Zhonghua Xue Ye Xue Za Zhi; 2016 Jun; 37(6):491-6. PubMed ID: 27431074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical features, therapeutic responses, and prognosis of the patients with mantle cell lymphoma.
    Ying ZT; Zheng W; Wang XP; Xie Y; Tu MF; Lin NJ; Ping LY; Liu WP; Deng LJ; Zhang C; Zhu J; Song YQ
    Chin J Cancer; 2012 Jul; 31(7):348-53. PubMed ID: 22704490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can the prognosis of mantle cell lymphoma be predicted by simple CBC counts?
    Haydaroglu Sahin H
    Medicine (Baltimore); 2019 Jul; 98(30):e16180. PubMed ID: 31348229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma.
    Yoo C; Yoon DH; Kim S; Huh J; Park CS; Park CJ; Lee SW; Suh C
    Hematol Oncol; 2016 Mar; 34(1):22-7. PubMed ID: 25689467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cytarabine and hematopoietic cell transplantation for mantle cell lymphoma. Analysis of 20 patients].
    Campbell J; Hurtado S; Kutz C; Soto K; Ernst D
    Rev Med Chil; 2019; 147(1):9-17. PubMed ID: 30848759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network.
    Aukema SM; Hoster E; Rosenwald A; Canoni D; Delfau-Larue MH; Rymkiewicz G; Thorns C; Hartmann S; Kluin-Nelemans H; Hermine O; Dreyling M; Klapper W
    Blood; 2018 Jan; 131(4):417-420. PubMed ID: 29196411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic model for mantle cell lymphoma in the rituximab era: a nationwide study in Japan.
    Chihara D; Asano N; Ohmachi K; Kinoshita T; Okamoto M; Maeda Y; Mizuno I; Matsue K; Uchida T; Nagai H; Nishikori M; Nakamura S; Ogura M; Suzuki R
    Br J Haematol; 2015 Sep; 170(5):657-68. PubMed ID: 25953436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT).
    Geisler CH; Kolstad A; Laurell A; Räty R; Jerkeman M; Eriksson M; Nordström M; Kimby E; Boesen AM; Nilsson-Ehle H; Kuittinen O; Lauritzsen GF; Ralfkiaer E; Ehinger M; Sundström C; Delabie J; Karjalainen-Lindsberg ML; Brown P; Elonen E;
    Blood; 2010 Feb; 115(8):1530-3. PubMed ID: 20032504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2017 Aug; 92(8):806-813. PubMed ID: 28699667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated soluble IL-2Rα, IL-8, and MIP-1β levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphoma.
    Sonbol MB; Maurer MJ; Stenson MJ; Allmer C; LaPlant BR; Weiner GJ; Macon WR; Cerhan JR; Witzig TE; Gupta M
    Am J Hematol; 2014 Dec; 89(12):E223-7. PubMed ID: 25164110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.